Vericel Corporation (VCEL) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 3[1].
Trial NCT06915233[3] evaluates autologous cultured chondrocytes on porcine collagen membrane in Chondral Defect with a target enrollment of 309 participants. Trial NCT03588975[4] evaluates MACI in Chondral Defect with a target enrollment of 45 participants.
VCEL has 3 Form 4 insider filings recorded at the SEC in the past 30 days[5].